KTE-X19

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

6 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Patients with no available curative treatment options with leukemia are eligible to participate in this study to test an experimental approach called gene transfer that involves B cells. This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at motleyl [at] chop.edu or 267-426-6857.

Eligibility & Criteria

IRB #:
16-013488
Official Title:
A Phase 1/2 Multi-center Study Evaluating The Safety And Efficacy Of Kte-x19 In Pediatric And Adolescent Subjects With Relapsed/refractory B-precursor Acute Lymphoblastic Leukemia Or Relapsed/refractory B Cell Non Hodgkin Lymphoma (Zuma-4)
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 21 Years
Gender:
All
Study Categories:
Leader
Stephan A. Grupp

Stephan A. Grupp, MD, PhD